Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | DRD2 | P14416 | 2/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3452875 | 0.84 | KDM4E (0.66) | KDM4ETSHRDRD2DRD4MEN1 | |
| SCHEMBL3453818 | 0.83 | KDM4E (0.58) | KDM4ETSHRDRD2DRD4MEN1 | |
| SCHEMBL13698425 | 0.81 | KDM4E (1.00) | KDM4ETSHRDRD2DRD4MEN1 | |
| SCHEMBL3452824 | 0.80 | KDM4E (0.61) | KDM4ETSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL3454318 | 0.80 | KDM4E (0.61) | KDM4ETSHRDRD4MEN1KMT2A | |
| SCHEMBL3453365 | 0.79 | KDM4E (0.60) | KDM4ETSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL3453457 | 0.79 | KDM4E (0.60) | KDM4ETSHRDRD4MEN1KMT2A | |
| SCHEMBL3453593 | 0.79 | KDM4E (0.74) | KDM4ETSHRDRD2DRD4MEN1 | |
| SCHEMBL3453491 | 0.77 | KDM4E (0.54) | KDM4ETSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL3453766 | 0.77 | KDM4E (0.62) | KDM4ETSHRDRD4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820817-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | claimed |
| US-20100105693-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | US | claimed |
| EP-1753429-A1 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-02-21 | — | — | EP | claimed |
| US-20060019962-A1 | substituted piperazine compounds that are useful modulators of muscarinic receptors; 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine; treatment of COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and pain | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-26 | — | — | US | claimed |
| WO-2005117883-A1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-12-15 | — | — | WO | claimed |
| US-7820817-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100105693-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | US | disclosed |
| US-20060019962-A1 | substituted piperazine compounds that are useful modulators of muscarinic receptors; 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine; treatment of COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and pain | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105693-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | KDM4E 2719/4885TSHR 86/4885DRD2 532/4885 |
| US-20060019962-A1 | substituted piperazine compounds that are useful modulators of muscarinic receptors; 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine; treatment of COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and pain | ACHE, CHRM5, CHRM3 | KDM4E 2477/4885TSHR 1763/4885DRD2 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.